"During the first quarter of 2012, we updated our clinical development plan for KRYSTEXXA and are undertaking a targeted and focused approach to expanding the clinical utility of KRYSTEXXA into populations beyond RCG. For example, a significant number of severe gout patients have underlying chronic renal disease that can affect treatment options. Clinicians are reluctant to use conventional urate lowering agents in patients with significant renal disease and when they do use them, it is often in doses that have little effect on serum uric acid levels. Further, in patients with gout who have undergone solid organ transplantation, including renal transplantation, the use of conventional urate lowering treatments is actually contraindicated in many of those patients receiving certain types of immunosuppressive agents. Certain results observed in the Phase 3 clinical trials for KRYSTEXXA support effective treatment with KRYSTEXXA in these circumstances. In view of these findings, a key area of focus for our clinical development plan will be to confirm whether KRYSTEXXA is dialyzable. A study looking at the use of KRYSTEXXA in patients undergoing renal dialysis has completed enrollment and we expect data in mid-2013."
This is NOT a huge market. It is for a very SMALL sub set of patients undergoing dialysis that also have SEVERE gout. Anyhow, the results of K in patients undergoing dialysis should be released with the pending quarterly results. If they are positive, the share price might double and SVNT might actually find a willing acquirer for $2/sh or so.